title: Development of novel elastic vesicle-based topical formulation of cetirizine dihydrochloride for treatment of atopic dermatitis.
abstract: Cetirizine is a piperazine-derived second-generation antihistaminic drug recommended for treatment of pruritus associated with atopic dermatitis. The present investigation encompasses development of a nanosized novel elastic vesicle-based topical formulation of cetirizine dihydrochloride using combination of Phospholipon® 90G and edge activators with an aim to have targeted peripheral H1 antihistaminic activity. The formulation was optimized with respect to phospholipid/drug/charge inducer ratio along with type and concentration of edge activator. The optimized formulation was found to be satisfactory with respect to stability, drug content, entrapment efficiency, pH, viscosity, vesicular size, spreadability, and morphological characteristics. The ex vivo permeation studies through mice skin were performed using Franz diffusion cell assembly. It was found that the mean cumulative percentage amount permeated in 8 h was almost twice (60.001 ± 0.332) as compared to conventional cream (33.268 ± 0.795) and aqueous solution of drug (32.616 ± 0.969), suggesting better penetration and permeation of cetirizine from the novel vesicular delivery system. Further, therapeutic efficacy of optimized formulation was assessed against oxazolone-induced atopic dermatitis in mice. It was observed that the developed formulation was highly efficacious in reducing the itching score (4.75 itches per 20 min) compared to conventional cream (9.75 itches per 20 min) with profound reduction in dermal eosinophil count and erythema score. To conclude, a novel vesicular, dermally safe, and nontoxic topical formulation of cetirizine was successfully developed and may be used to treat atopic dermatitis after clinical investigation.
authors: Shishu
authors: S
authors: Goindi
authors: Gautam
authors: G
authors: Kumar
authors: Neeraj
authors: N
authors: Kumar
authors: Amanpreet
authors: A
authors: Kaur
mesh_terms: D000287:Administration, Topical; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D017332:Cetirizine / Q000008:administration & dosage* / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004339:Drug Compounding; D004548:Elasticity; D004563:Electrochemistry; D005079:Excipients; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D008055:Lipids / Q000737:chemistry; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D046529:Microscopy, Electron, Transmission; D009824:Ointments; D010316:Particle Size; D019999:Pharmaceutical Solutions; D010743:Phospholipids / Q000737:chemistry; D012867:Skin / Q000378:metabolism; D012869:Skin Absorption
chemical_list: D018926:Anti-Allergic Agents; D005079:Excipients; D008055:Lipids; D008081:Liposomes; D009824:Ointments; D019999:Pharmaceutical Solutions; D010743:Phospholipids; D017332:Cetirizine
references: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S138-49
references: 19932921
references: Biochim Biophys Acta. 1983 May 24;737(2):285-304
references: 6342675
references: J Invest Dermatol. 2008 Jan;128(1):79-86
references: 17671515
references: Int J Pharm. 2001 May 21;219(1-2):61-72
references: 11337166
references: Crit Rev Ther Drug Carrier Syst. 1996;13(3-4):257-388
references: 9016383
references: Dis Model Mech. 2013 Jan;6(1):125-34
references: 22822046
references: J Control Release. 2000 Apr 3;65(3):403-18
references: 10699298
references: AAPS J. 2004 Aug 10;6(3):e18
references: 15760103
references: J Pharm Pharmacol. 2001 Aug;53(8):1069-77
references: 11518016
references: Drugs. 1990 Nov;40(5):762-81
references: 1981354
references: Int J Pharm. 2001 Oct 9;228(1-2):43-52
references: 11576767
references: Int J Pharm. 2005 Jul 14;298(1):1-12
references: 15896932
references: Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1995 Oct;52(4):4198-4208
references: 9963891
references: Drugs. 2004;64(5):523-61
references: 14977391
references: Int J Pharm. 2008 Sep 1;361(1-2):104-11
references: 18577437
references: Ann Allergy Asthma Immunol. 2004 Nov;93(5):460-4
references: 15562885
references: Drug Dev Ind Pharm. 2003 Oct;29(9):1013-26
references: 14606665
references: Int J Pharm. 2012 Nov 1;437(1-2):277-87
references: 22939964
references: Eur J Pharmacol. 2011 Sep 30;667(1-3):383-8
references: 21664903
references: AAPS PharmSciTech. 2012 Mar;13(1):67-74
references: 22130790
references: Expert Opin Drug Deliv. 2006 Nov;3(6):727-37
references: 17076595
references: Int Immunopharmacol. 2009 Apr;9(4):403-11
references: 19162238
references: Int J Pharm. 2002 Jul 25;241(2):319-27
references: 12100859